Journal profile · Pharmacology & Pharmacy
Medicinal Research Reviews
ISSN 0198-6325 · eISSN 1098-1128 · John Wiley and Sons Inc. · UNITED STATES · Bimonthly · Founded 1981
Medicinal Research Reviews: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 13.51; hybrid open access; APC about USD 4,980; median 184 days to acceptance (87 articles, last 24 months); community-reported acceptance: mostly invited papers; 71 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Medicinal Research Reviews is published by John Wiley and Sons Inc. and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Computational Drug Discovery Methods, Receptor Mechanisms and Signaling and Chemical Synthesis and Analysis, together about 20.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Medicinal Research Reviews publishes timely, critical reviews and opinion-based articles on topics related to medicinal research, broadly defined, to which the authors have made significant contributions. Appropriate topics include, but are not limited to, the underlying pathophysiology of important diseases and disease vectors; therapeutic approaches to the treatment of various diseases; the properties of molecular targets for therapeutic agents; important new methodologies facilitating the search for therapies; genomics, proteomics and metabolomics; structure-activity correlations of drug series; the development of new imaging and diagnostic tools; drug metabolism; drug delivery; chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of important drugs. veterinary drugs, pharmaceutical analysis, pharmaco-toxicological analysis, therapeutic drug monitoring, omics-driven drug discovery, translational medicinal research, artificial intelligence and machine learning in drug discovery and development, policy makers and innovation strategists in pharmaceutical sciences. All submissions are welcome for consideration. Authors are asked to include a "Review Summary Sheet" with their submission. This Sheet is available for download here and more details can be found in the Author Guidelines. Please note: Systematic Reviews and Meta-Analyses (e.g. PRISMA http://www.prisma-statement.org) are outside the scope of Medicinal Research Reviews due to the generation of new data as part of the analysis.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Laura MercoliniPublisher website
Editorial board by country: 5 in mainland China (about 18%); most named United States 9, Mainland China 5, Italy 5, Portugal 2, Hong Kong, China 1 (28 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Computational Drug Discovery MethodsComputer Science7.9%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology7.4%
- Chemical Synthesis and AnalysisBiochemistry, Genetics and Molecular Biology5.1%
- HIV/AIDS drug development and treatmentMedicine4.8%
- Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology4.6%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4.5%
- Click Chemistry and ApplicationsChemistry4.4%
- Protein Degradation and InhibitorsBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Chemistry, Medicinal | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Chemistry, Medicinal | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Chemistry, Medicinal | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 13.51LetPub ·
- Impact factor (publisher)
- 13.6Publisher website ·
- Impact factor (publisher) 2025
- 13.6Publisher website ·
- CiteScore 2026-06
- 29.1LetPub ·
- CiteScore (publisher)
- 29.1Publisher website ·
- CiteScore (publisher) 2025
- 29.1Publisher website ·
- SJR 2026-06
- 3.27LetPub ·
- SNIP 2026-06
- 3.04LetPub ·
- h-index
- 119LetPub ·
- h-index
- 194OpenAlex ·
- i10-index
- 1,359OpenAlex ·
- 2-year mean citedness
- 9.95OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 29.15%LetPub ·
Volume
- Articles per year
- 57LetPub ·
- Articles per year (publisher) 2025
- 57Publisher website ·
- Downloads per year (publisher) 2025
- 459,415Publisher website ·
Articles by year OpenAlex count · 2,108 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 78 | 35 | 39 |
| 2025 | 71 | 33 | 480 |
| 2024 | 88 | 54 | 1,838 |
| 2023 | 89 | 49 | 3,390 |
| 2022 | 54 | 15 | 2,373 |
| 2021 | 95 | 31 | 5,398 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
184 daysMedian, submission to acceptance · P25–P75 119 days – 243 days
- Acceptance to online
- median 14 days (87 articles)
- Submission to online
- median 202 days
- Sample
- 87 articles with submission and acceptance dates (152 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average acceptance (community reports)
- Mostly invited papersLetPub ·
- Acceptance rate (publisher)
- 8%Publisher website ·
- Acceptance rate (publisher) 2025
- 8%Publisher website ·
- Submission to first decision
- 23 daysPublisher website ·
- Submission to first decision 2025
- 23 daysPublisher website ·
- Submission to acceptance 2025
- 252 daysPublisher website ·
- Acceptance to publication 2025
- 18 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,980 / EUR 4,170 / GBP 3,300 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- AMA
- First submission
- Free format: the journal's layout is not required
- Not considered
- Systematic Reviews and Meta-Analyses
Article types accepted9, with length limits
- meta-analysisMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
- mini reviewMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…main text ≤ 3,500 words · abstract ≤ 250 words
- opinionMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
- original research articleMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
- perspectiveMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
- reviewMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
- review articleMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…main text ≤ 10,000 words · abstract ≤ 250 words
- systematic reviewMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
- viewpointMedicinal Research Reviews is a review-only journal; original research articles are beyond the scope of the journal. Authors interested in publishing an origina…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, License & copyright, Open access, Peer review, Preprints
- Authorship Authorship
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review editorial standards and scroll down for a description of authorship criteria.
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
Journal encourages data sharing; authors review Wiley's Data Sharing policy to select appropriate data availability statement. Model summary
This journal encourages data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.
Source ↗Publisher website ·- License & copyright Reproduction of Copyright Material
Uses CC-BY/CC-BY-NC/CC-BY-NC-ND Creative Commons License. Model summary
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ.
Source ↗Publisher website ·- Open access Open Access
ORCID required for corresponding author. Model summary
This journal is a subscription journal that offers an open access option. You’ll have the option to choose to make your article open access after acceptance, which will be subject to an APC. You can read more about APCs and whether you may be eligible for waivers or discounts, through your institution, funder, or a country waiver.
Source ↗Publisher website ·- Peer review 1. Submission and Peer Review Process
Single-anonymized peer review model; papers only sent to review if Editor-in-Chief determines quality and relevance requirements are met. Model summary
Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal. You may check the status of your submission at anytime by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact submissionhelp@wiley.com. For help with submissions, p…
Source ↗Publisher website ·- Preprints
Preprint policy: journal accepts articles previously published on preprint servers; considers preprints for review; allows posting submitted version to preprint server at any time; requests updating pre-publication versions with link to final published article. Model summary
This journal accepts articles previously published on preprint servers. Medicinal Research Reviews will consider for review articles previously available as preprints. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1981
- ISSN
- 0198-6325
- Electronic ISSN
- 1098-1128
- Latest issue on the website
- Volume 46, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Medicinal Research Reviews
What CAS zone is Medicinal Research Reviews in?
In the 2025 upgraded edition of the CAS Journal Ranking, Medicinal Research Reviews is in Zone 1 of Medicine, and in Zone 1 of the minor category Chemistry, Medicinal / Pharmacology & Pharmacy; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Medicinal Research Reviews?
The latest impact factor listed by LetPub is 13.51; CiteScore 29.1, h-index 194.
How long does peer review take at Medicinal Research Reviews?
Based on the dates recorded on 87 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 184 days (interquartile range 119–243 days); the community-reported acceptance is “Mostly invited papers”; the journal's website gives an acceptance rate of 8% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Medicinal Research Reviews?
According to the journal's author guidelines: Reference style: AMA; First submission: Free format: the journal's layout is not required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Medicinal Research Reviews based?
Of the 28 board members whose country the journal's board page names, 5 (about 18%) are in mainland China; the countries named most often are United States (9), Mainland China (5) and Italy (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Medicinal Research Reviews?
According to LetPub and DOAJ records, Medicinal Research Reviews is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Medicinal Research Reviews open access, and what is the APC?
Medicinal Research Reviews is a hybrid journal. For open-access publication: APC about USD 4,980.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .